Introduction
============

Injection drug users (IDUs) now represent one of the largest reservoirs of HIV infection in the United States, contributing to the fastest spread of the virus ([@B2]; [@B44]). IDUs frequently use heroin, the most commonly abused opiate ([@B28]). Opiate use is associated with the worst health outcomes in HIV-infected individuals, as they adversely impact the human immune system. Clinical and epidemiological evidence from pre-AIDS studies indicate that opiates (particular heroin) play a cofactor role in the pathogenesis of HIV infection ([@B11]; [@B45]; [@B51]; [@B30]; [@B67]). *In vitro* studies from different laboratories also provide direct evidence that opiates (morphine) facilitate HIV infection of the target cells. Morphine enhanced HIV replication in human monocytes/macrophages ([@B17]; [@B19]; [@B25]; [@B63]), T lymphocytes ([@B9]; [@B53]; [@B39]), kupffer cells ([@B49]), human neuroblastoma cells ([@B52]), and human brain cells ([@B7]; [@B40]; [@B43]).

The enhancing effect of opiates on HIV is likely due to their negative impact on the host immune defense mechanisms. Opiates are known to have a profound effect on the immune system ([@B60]; [@B64]; [@B47]). To date, the immunosuppressive effects of opiates have been extensively investigated in the major cell types of the immune system, including natural killer cells, T cells, B cells, macrophages and polymorphonuclear leukocytes ([@B6]; [@B13]; [@B5]; [@B41]). Macrophages, as a primary target of HIV infection, are among the first cells infected by HIV and late function as a reservoir for the virus. Although opioids have been shown to modulate the function of macrophages, there is limited information about the specific actions of opiates, particularly heroin, on intracellular antiviral innate immunity that controls HIV replication in macrophages. Earlier studies reported that morphine suppressed the production of type I interferons (IFNs; [@B38]; [@B59]), the key cytokines that modulate all phases of immune processes and play a central role in host innate immunity against viral infections. In response to viral infections, IFN-α/β can trigger down-stream cell signaling and subsequent induction of many IFN-stimulated genes (ISGs) and other antiviral factor. IFN-α/β also induce antiviral miRNAs ([@B36]; [@B68]; [@B10]). Studies have demonstrated that the miRNAs participate in the host immune responses to viral infections, including HIV ([@B22]; [@B62]; [@B24]). In general, the miRNAs interfere with HIV replication by either directly binding to viral RNAs or targeting the cellular factors that are related to HIV survival ([@B22]; [@B23]; [@B8]). Several cellular miRNAs (miR-28, 29a, 125b, 150, 198, 223, and 382) have been identified to target a set of accessory genes of HIV ([@B18]; [@B1]; [@B33]; [@B54]; [@B62]). For example, these HIV restriction miRNAs can target the 3′UTR of HIV transcripts, potentially rendering productive infection of HIV into latency in resting CD4^+^ T lymphocytes ([@B22]). We reported that monocytes from peripheral blood are enriched with some of these HIV restriction miRNA, which contribute to the resistance of monocytes to HIV infection ([@B62]). Given the key role of the HIV restriction miRNAs in intracellular innate immunity, it is of significance to determine whether environmental factors such as heroin abuse can dysregulate these miRNAs in the target cells of HIV.

Materials and Methods {#s1}
=====================

Study Subjects
--------------

Fourteen heroin addicts and eight control subjects were recruited by the Wuhan Center for Disease Prevention and Control (Wuhan CDC) in China. Informed consent was obtained from the study subjects, and the Institutional Research Board of the Wuhan CDC approved this study. The majority (\>80%) of heroin users in China use heroin only ([@B27]). Polydrug use was excluded based on the self-report and Urine Screen. All the subjects were current heroin users as their urine tests were positive for opiate at the time of enrollment. The control subjects were recruited using convenience sampling from the community in which the study site was located. Subjects were excluded if they had a chronic systemic illness (cardiac, renal, pulmonary, hepatic, endocrine, metabolic, or autoimmune disorders), major psychiatric disorders or if they were abusing other substances other than heroin (urine drug test). Control subjects with no history of drug or alcohol abuse were also excluded if they had major medical or psychiatric disorders. All the study subjects were negative for HIV and HCV.

Cell Isolation and Culture
--------------------------

Peripheral blood samples were obtained from healthy adult donors without a known history of drug abuse, and identified as HIV-1 antibody negative. Monocytes were purified as per the previously described technique ([@B62], [@B63]). In brief, heparinized blood is separated by centrifugation over Lymphocyte Separation Medium at 400--500X*g* for 45 min. The mononuclear layer is collected and incubated with Dulbecco's Modified Eagle's Medium (DMEM) in 2% gelatin-coated flasks for 45 min at 37°C, followed by removal of the non-adherent cells with DMEM. Following the initial purification, at least 97% of the cells are monocytes, as determined by flow cytometry analysis using a monoclonal antibody against CD14, a marker specific for monocytes and macrophages. Purified monocytes are plated in 48-well culture plates (0.25 × 10^6^ cells/well) or 96-well culture plates (10^5^ cells/well) in DMEM containing 10% fetal calf serum (FCS) for 7 days. Monocyte-derived macrophages (MDMs) refer to 7-days-cultured macrophages.

RNA Extraction and Real-time RT-PCR
-----------------------------------

Total cellular RNA, including miRNA, was extracted from the cells using the miRNeasy Mini Kit from QIAGEN (Valencia, CA, USA). Total RNA (1μg) was reverse-transcribed with the miScript Reverse Transcription Kit from QIAGEN. Real-time RT PCR for the quantification of a subset of miRNAs (miRNA-28, miRNA-125b, miRNA-150, miRNA-382, miRNA-223, miRNA-122, Let-7c, and miRNA-124a) was carried out with miScript Primer Assays and the miScript SYBR Green PCR Kit from QIAGEN as described ([@B62]). For mRNA detection, the resulting cDNA was then used as a template for real-time PCR quantification. Real-time PCR was performed with 1/10 of the cDNA with specific primers for the quantification of IFN-α/β, and GAPDH gene expression with the iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) ([@B69], [@B68]). The oligonucleotide primers were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA). The specific oligonucleotide primers used wereas follows: IFN-α:5′-TTTCTCCTGCCTGAAGGAC-AGAG-3′ (sense) and 5′-GCTCATGATTTCTGCTCTGACA-3′ (antisense) ([@B56]); IFN-β: 5′-GCCGCATTGACCATCTATGAGA-3′ (sense) and 5′-GAGATCTTCAGTTTCGGAGG-TAAC-3′ (antisense); GAPDH (the house keeping gene):5′- GGTGGTCTCCTCTGACTTCAACA-3′ (sense) and 5′-GTTGCTGTAGCCAAATTCGTTGT-3′ (anti-sense). The IFN-α primer pair matches 11 IFN-α subtypes: IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA14, IFNA16, IFNA17, and IFNA21.

HIV Strains and Other Reagents
------------------------------

Based on their differential use of the major HIV receptors (CCR5 and CXCR4), HIV isolates can be classified to R5, X4, and R5X4 strains ([@B4]). HIV Bal and JRFL strains (R5 tropic) were obtained from the AIDS Research and Reference Reagent Program at the NIH (Bethesda, MD, USA). HIV JAGO strain (R5 tropic) was obtained from the Center for AIDS Research at the School of Medicine, University of Pennsylvania. Heroin was kindly provided by Dr. Martin Adler from Temple University, Center for Substance Abuse Research through the NIDA drug supply program. Naltrexone was obtained from Sigma (St Louis, MO, USA).

Heroin and/or Naltrexone Treatment
----------------------------------

Seven-days-cultured macrophages (10^5^ cells/well in 96-well plates, or 2.5 × 10^5^ cells/well in 48-well plates) with or without heroin were incubated at different concentrations (10^-9^M to 10^-6^M) for 6 h. The selection of these concentrations of heroin was based on studies by others ([@B59]; [@B43]) and us ([@B17]; [@B61], [@B65]). To investigate whether naltrexone blocks the heroin action, we treated the macrophages for 1 h with naltrexone (10^-6^M), followed by heroin treatment.

Infection of Macrophages with HIV
---------------------------------

Seven-days-cultured macrophages were infected with equal amounts of cell-free HIV Bal, JAGO, or JRFL strain for 2 h at 37°C after treatment with or without heroin. Cells were then washed three times with plain DMEM, to remove any unabsorbed virus, and fresh media containing heroin and/or naltrexone was added to the cell culture. Untreated cell served as a control. Culture supernatant was harvested at day 6, 10, and 12 postinfection for RT assay.

HIV RT Assay
------------

HIV RT activity was determined based on the technique ([@B66]) with modifications ([@B20]). In brief, 10 μl of culture supernatant from macrophages infected with or without HIV was added to a cocktail containing poly(A), oligo(dT) (Amersham Biosciences, Inc., Piscataway, NJ, USA), MgCl~2~, and \[32P\]dTTP (Amersham Biosciences, Inc.), and incubated for 24 h at 37°C. 30 μl of the cocktail was spotted onto DE81 paper (Whatman Internatianl Ltd, England), then dried and washed five times with 2 x saline-sodium citrate buffer and once with 95% ethanol. The filter paper was then air-dried. Radioactivity was counted in a liquid scintillation counter (PerkinElmer Life Sciences, Boston, MA, USA).

Statistical Analysis
--------------------

A student's *t*-test was used to evaluate the significance of the differences between groups, and multiple comparisons were performed by regression analysis and one-way analysis of variance. Statistical analyses were performed with Graphpad Instat Statistical Software (Graphpad Software Inc., San Diego, CA, USA), and all data is presented as the mean ± SD. Statistical significance was defined as *P* \< 0.05.

Results
=======

Heroin Enhances HIV Infection of Macrophages
--------------------------------------------

We first determined the dose effect of heroin on HIV infection of macrophages. Heroin treatment enhanced the susceptibility of macrophages to infection with HIV Bal, JAGO, and JRFL strains, as evidenced by increased RT activity at day 12 postinfection (**Figure [1A](#F1){ref-type="fig"}**). We also examined the time course effect of heroin treatment on HIV infection of macrophages. As demonstrated in **Figure [1B](#F1){ref-type="fig"}**, heroin treatment increased HIV RT activity at different time points post infection. We further examined the effect of an opioid receptor antagonist on heroin-mediated enhancement of HIV RT activity. The pretreatment of macrophages with the opioid receptor antagonist (naltrexone) completely abrogated the enhancing effect of heroin on HIV RT activity (**Figure [2](#F2){ref-type="fig"}**).

![**Heroin enhances HIV infection of macrophages.** **(A)** Seven-day cultured macrophages were incubated with or without heroin at indicated concentrations for 6 h prior to different HIV strain (Bal, JRFL, or JAGO) infection. HIV RT activity was determined at day 12 postinfection. **(B)** Seven day cultured macrophages were incubated with or without heroin at the indicated concentrations for 6 h prior to HIV (Bal) infection. HIV RT activity was determined at day 6, 10, and 12 postinfection. Cell culture supernatant was collected at the indicated time points and subjected to RT assay to detect HIV RT activity. The data shown is the mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, heroin vs. control).](fmicb-06-01230-g001){#F1}

![**Naltrexone blocks the heroin-mediated enhancement of HIV.** Seven-day cultured macrophages were incubated with or without heroin at the indicated concentrations for 6 h prior to HIV Bal, JRFL, or JAGO infection. Naltrexone (10^-6^ M) was added to the macrophages cultures for 1 h prior to heroin (10^-7^ M) treatment. HIV RT activity was determined at day 12 postinfection. Cell culture supernatant was collected at the indicated time points and subjected to RT assay to detect the HIV RT activity. The data shown is the mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (^∗∗^*p* \< 0.01, heroin vs. heroin + naltrexone).](fmicb-06-01230-g002){#F2}

Heroin Inhibits HIV Restriction miRNAs
--------------------------------------

We first examined whether heroin has the ability to suppress the HIV restriction miRNAs in macrophages. As shown in **Figure [3](#F3){ref-type="fig"}**, heroin treatment of macrophages inhibited the expression of four HIV restriction miRNAs (miRNA-28, miRNA-125b, miRNA-150, and miRNA-382). The highest inhibition by heroin was observed at a concentration of 10^-7^M (**Figure [3B](#F3){ref-type="fig"}**). In contrast, heroin treatment of macrophages had little effect on the expression of miRNA-223, miRNA-124a, Let-7c, and miRNA-122 (**Figure [3A](#F3){ref-type="fig"}**). Since heroin-mediated enhancement of HIV infection could be blocked by naltrexone (**Figure [2](#F2){ref-type="fig"}**), we examined the effect of naltrexone on heroin-mediated inhibition of anti-HIV factor expression. As shown in **Figure [4](#F4){ref-type="fig"}**, naltrexone completely abrogated the suppressing effect of heroin on anti-HIV miRNA expression, whereas naltrexone alone had little effect on anti-HIV miRNA expression (**Figure [4](#F4){ref-type="fig"}**).

![**Heroin inhibits HIV restriction miRNAs.** **(A)** Effect of heroin on miRNA expression in macrophages. Seven-day cultured macrophages were cultured in the presence or absence of heroin at the indicated concentration (10^-7^ M) for 6 h. Total cellular RNA was then extracted from cell cultures and subjected to real-time RT-PCR for miRNA-28, miRNA-125b, miRNA-150, miRNA-382, miRNA-223, miRNA-122, miRNA-124a, and Let-7c expression. Data is given as a mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 for heroin vs. control). **(B)** Seven-day cultured macrophages were incubated in the presence or absence of heroin at the indicated concentrations for 6 h. Total cellular RNA extracted from cell cultures was subjected to realtime RT-PCR for miRNA expression, miRNA-28, miRNA-125b, miRNA-150, and miRNA-382. The data shown is the mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, heroin vs. control).](fmicb-06-01230-g003){#F3}

![**Naltrexone blocks the heroin action on HIV restriction miRNAs.** Naltrexone (10^-6^ M) was added to macrophage cultures for 1 h prior to heroin treatment. Total cellular RNA was then extracted from the cell cultures 6 h post-treatment and subjected to realtime RT-PCR for miRNA expression: miRNA-28 **(A)**, miRNA-125b **(B)**, miRNA-150 **(C)**, and miRNA-382 **(D)**. The data shown is the mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, heroin vs. control, or heroin + naltrexone).](fmicb-06-01230-g004){#F4}

Heroin Suppresses Type I IFNs
-----------------------------

Type I IFNs (IFN-α/β) are well known for their ability to inhibit a wide range of virus(s), including HIV. Although the anti-HIV mechanism(s) of IFN-α/β remain to be determined, many cellular factors including miRNAs have been identified as IFN-α/β-inducible anti-HIV elements in target cells ([@B3]; [@B48]; [@B50]; [@B35]; [@B37]; [@B22]; [@B31]; [@B34]; [@B42]; [@B57]; [@B58]). We thus examined whether heroin can suppress intracellular IFN-α and IFN-β expression in macrophages. As shown in **Figures [5A,B](#F5){ref-type="fig"}**, heroin treatment of macrophages, significantly suppressed IFN-α and IFN-β expression. The pretreatment of macrophages with naltrexone could block the effect of heroin on IFN-α and IFN-β expression (**Figures [5A,B](#F5){ref-type="fig"}**).

![**Heroin inhibits IFN-α and IFN-β.** Naltrexone (10^-6^ M) was added to the macrophage cultures for 1 h prior to heroin treatment. Total cellular RNA was then extracted from the cell cultures 6 h post-treatment and subjected to realtime RT-PCR for IFN-α **(A)** and IFN-β **(B)** expression. The data shown is the mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, heroin vs. control, or heroin + naltrexone).](fmicb-06-01230-g005){#F5}

*In Vivo* Impact of Heroin on HIV Restriction miRNAs
----------------------------------------------------

In order to confirm the *in vitro* action of heroin on the HIV restriction miRNAs, we examined the levels of these miRNAs in macrophages derived from monocytes of the heroin addicts and control subjects. As shown in **Figure [6](#F6){ref-type="fig"}**, heroin addicts had significantly lower levels of the HIV restriction miRNAs (miRNA-28, miRNA-125b, miRNA-150, and miRNA-382) than the control subjects. However, there was little difference in miRNA-223 levels between heroin addicts and control subjects (**Figure [6](#F6){ref-type="fig"}**).

![**Heroin users have decreased levels of HIV restriction miRNAs.** Total RNA was exacted from macrophages derived from monocytes of heroin addicts and normal control subjects. miRNA-28 **(A)**, miRNA-125b **(B)**, miRNA-150 **(C)**, miRNA-382 **(D)**, and miRNA-223 **(E)** was amplified using specific primers and quantified by real time RT-PCR. The results are expressed as relative transcript abundance of miRNA/GAPDH.](fmicb-06-01230-g006){#F6}

Discussion
==========

Injection of heroin use increases the risk of acquiring HIV ([@B15]; [@B46]) and progression to AIDS ([@B45]). However, because of the complexity of opioid addiction and/or HIV infection, it has been extremely difficult to compare different clinical and epidemiological findings in studying the impact of opioids on HIV disease progression ([@B12]). The majority of *in vitro* studies have shown that morphine enhances HIV infection of PBMC ([@B55]), CD4^+^ T cells ([@B9]; [@B53]; [@B39]), and macrophages ([@B17]; [@B26], [@B25]; [@B19]; [@B63], [@B65]). In the present study, we demonstrated for the first time that *in vitro* heroin treatment of macrophages increases HIV infection/replication with different strains (**Figure [1](#F1){ref-type="fig"}**). This effect of heroin on HIV was specific, as naltrexone could completely block the heroin action (**Figure [2](#F2){ref-type="fig"}**). We reported that human immune cells, including monocytes/macrophages, express functional μ opioid receptors ([@B17]; [@B19]; [@B63]).

To understand the mechanism(s) of heroin action on HIV, we examined whether heroin use has a negative impact on the intracellular HIV-associated miRNAs. It is now known that a number of cellular miRNAs participate in host cell innate immunity against viral infections, including HIV. We were particularly interested in miRNA-28, miRNA-125b, miRNA-150, miRNA-223, and miR-382, as they can target the HIV RNA 3-terminus (a highly conserved region of the virus), inhibiting the translation of almost all HIV encoded proteins, including Rev and Tat, the key players in HIV replication in CD4^+^ T cells and macrophages ([@B18]). These miRNAs are enriched in resting CD4^+^ T cells ([@B22]) and monocytes ([@B62]), which contribute to the intracellular immune defense against HIV. The finding that heroin could inhibit the expression of the HIV restriction miRNAs provides a plausible mechanism for heroin-mediated enhancement of HIV infection of macrophages. Interestingly, heroin appears to selectively inhibit the HIV restriction miRNAs. We found that the inhibitory effect of heroin was limited to four of these miRNAs (miRNA-28, -125b, -150, and -382), while miR-223 and miRNA-124a/Let-7c were not affected by heroin treatment (**Figure [3A](#F3){ref-type="fig"}**). miRNA-124a/let-7c is HIV replication required miRNAs ([@B14]), and miRNA-122 is a HCV-supportive miRNA ([@B16]; [@B29]).

These *in vitro* observations (**Figures [3](#F3){ref-type="fig"}** and **[4](#F4){ref-type="fig"}**) were confirmed in our *in vivo* investigation, showing that macrophages derived from monocytes of the heroin addicts had lower levels of four HIV restriction miRNAs (miRNA-28, -125b, 150, and 382) than those from the control subjects. Similarly, heroin use had little effect on miRNA-223 expression as compared to the control groups (**Figure [6](#F6){ref-type="fig"}**). This observation could be due to the fact that miRNA-223 is not an inducible miRNA by IFN-α/β. We reported ([@B68]) that although IFN-α/β could induce the expression of the HIV restriction miRNAs (miRNA-28, miRNA-125b, miRNA-150, and miRNA-382), they had little effect on miRNA-223 expression in macrophages.

The mechanism(s) of the heroin action on the HIV restriction miRNAs remains to be determined. However, it is likely that heroin-mediated suppression of type I IFNs is partially responsible for the heroin action on the miRNAs. As a potent inducer of antiviral activities, IFN-α/β plays a crucial role in host cell innate immunity. IFN-α/β can directly induce the expression of miRNAs that have antiviral activity. Our earlier study demonstrated that IFN-α/β treatment of macrophages induced the expression of the HIV restriction miRNAs ([@B68]). We also reported that morphine treatment of monocytes could inhibit the expression of several HIV restriction miRNAs ([@B63]). Studies by others showed that morphine suppressed IFN-α expression in PBMCs and T lymphocytes ([@B32]; [@B21]). In addition, morphine suppresses Sendai virus-induced IFN-α production by PBMCs ([@B32]). These findings support our observation that heroin could downregulate IFN-α/β expression in macrophages (**Figure [5](#F5){ref-type="fig"}**).

Conclusion
==========

Our study provides the compelling evidence that heroin enhances HIV replication in macrophages through the inhibition of the intracellular HIV restriction miRNAs. These findings support the notion that opioids compromise specific host innate defense mechanisms against HIV infection. Understanding how heroin abuse impairs specific immune responses to HIV infection should improve and advance our ability to treat HIV-infected heroin users. Nevertheless, future studies are necessary to reveal additional and unidentified mechanisms by which heroin damages the intracellular innate immunity that controls HIV in CD4^+^ T cells and macrophages.
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